Business & Industry

Eli Lilly & Co. is set to acquire Centessa Pharmaceuticals Plc in a transaction worth up to $7.8 billion, underscoring its push to broaden its drug development pipeline. The Centessa Pharmaceuticals deal highlights the company’s effort to expand into therapeutic...

Johnson & Johnson has received a key regulatory endorsement in Europe, marking a significant shift in how oncology treatments can be administered. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has approved a...

Japanese pharmaceutical company Otsuka has moved to deepen its presence in the emerging neuroplastogen space through an agreement to acquire Transcend Therapeutics, bringing with it a promising MDMA-based candidate targeting post-traumatic stress disorder (PTSD) and related psychiatric conditions. The...

Novartis has entered into an agreement to acquire biotech firm Excellergy, a move that will bring a next-generation anti-immunoglobulin e (IgE) programme into its pipeline. Excellergy acquisition is structured at up to $2bn in upfront and milestone payments and...

Eli Lilly has expanded its engagement with Insilico Medicine, formalising a new AI drug discovery collaboration valued at up to $2.75 billion, further extending a relationship that began with an AI software licensing agreement in 2023. The latest agreement...

Daiichi Sankyo has formalised a strategic agreement with Tempus AI aimed at accelerating the clinical trajectory and differentiation of an antibody drug conjugate programme within oncology. The collaboration centres on integrating advanced AI capabilities into drug development workflows, with...

The U.S. Food and Drug Administration has initiated a new phase of stakeholder engagement for its national priority voucher pilot program, announcing a public meeting scheduled for June 12, 2026, alongside a Federal Register Notice seeking industry feedback. The...